Huntington's Disease Continues to Baffle Biopharma

Huntington’s disease might just top the list of intractable neurodegenerative diseases.

In October alone, Atlas Venture-funded Triplet Therapeutics shut down, citing recent failures in the space, NeuBase halted development of its Huntington’s program and PTC Therapeutics paused the U.S. arm of a Phase II trial following an FDA request for additional data.